Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8 -50.00% 3-Year EBITDA Growth Rate is 35.20% as of Dec. 2025, which is 34% above its 10-year median of 26.35. The stock has 6 warning signs investors should review. Among 808 Drug Manufacturers companies, BPH Global ranks better than 82.55% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 32.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BPH Global was 89.10% per year. The lowest was -63.10% per year. And the median was 26.35% per year.
BPH Global (ASX:BP8) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BPH Global 3-Year EBITDA Growth Rate Related Terms
ASX:BP8 vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BPH Global's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.20% mean?
BPH Global (ASX:BP8) has a 3-Year EBITDA Growth Rate of 35.20% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BPH Global and its competitors. This is 34% above median its historical median of 26.35. According to the industry distribution chart, BPH Global ranks #141 out of 808 companies in the Drug Manufacturers industry, placing it in the top 17.5%.
Is BPH Global's 3-Year EBITDA Growth Rate too high?
BPH Global's current 3-Year EBITDA Growth Rate of 35.20% is 34% above median its 10-year median of 26.35. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. BPH Global's value of 35.20% is 300% above this industry median. Based on the distribution chart, BPH Global ranks #141 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does BPH Global's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #141 out of 808 companies for 3-Year EBITDA Growth Rate. This places BPH Global in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. BPH Global's value of 35.20% is 300% above this benchmark. While the company's 10-year median is 26.35 vs. the industry median of 8.80, BPH Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BPH Global's current 3-Year EBITDA Growth Rate of 35.20% is 300% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BPH Global and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current 3-Year EBITDA Growth Rate is 35.20%, which is 34% above median its own 10-year median of 26.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current 3-Year EBITDA Growth Rate of 35.20%. The current 3-Year EBITDA Growth Rate is 35.20%, which is 34% above median its 10-year median of 26.35 and 300% above the Drug Manufacturers industry median of 8.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current 3-Year EBITDA Growth Rate is 35.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
